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Verbal and visuospatial deficits in
dementia with Lewy bodies
David K. Johnson, PhD; John C. Morris, MD; and James E. Galvin, MD, MPH
Abstract—Objective: To investigate the cognitive decline in dementia with Lewy bodies (DLBs) and characterize the
contribution of Lewy bodies (LBs) to cognitive impairment in the presence of concurrent Alzheimer disease (AD). Methods:
Cognitive deficits and rates of progression attributable to DLB and AD neuropathology were investigated in three groups
of participants from the longitudinal cohort of the Alzheimer Disease Research Center at Washington University with
autopsy-confirmed diagnoses of pure DLB (n  9), mixed DLB/AD (n  57), and pure AD (n  66). Factor analysis was
used to recover latent constructs in a comprehensive psychometric test battery, analysis of variance was used to test group
differences on the observed dimensions, and random effects models were used to test longitudinal rates of cognitive
decline. Results: Patients with AD pathology performed worse on the verbal memory dimension. Patients with LB
pathology performed worse on the visuospatial dimension. Combined pathology affected visuospatial performance but not
verbal memory. The rate of cognitive decline in the DLB, DLB/AD combined, and the pure AD groups was equivalent.
Conclusions: The comorbid presence of DLB and AD alters the cognitive presentation of visuospatial deficits in dementia
but does not alter dementia progression. Both visuospatial and verbal abilities declined at similar rates across the three
patient groups. DLB diagnosis may be improved, particularly when there is comorbid AD, by using domain-specific
testing.
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In contrast to the neuritic plaques and neurofibril-
lary tangles of Alzheimer disease (AD), dementia
with Lewy bodies (DLB) is characterized by
-synuclein inclusions (i.e., Lewy bodies [LBs]) in
neocortical, limbic, and subcortical regions. DLB and
associated disorders of -synuclein aggregation
(synucleinopathies) are the second most common
cause of neurodegenerative dementia after AD.1 Al-
though a minority of DLB cases have only LBs at
autopsy (“pure” DLB), the more common finding is a
mixture of LBs with sufficient burden of neuritic
plaques and neurofibrillary tangles to also diagnose
AD (mixed DLB/AD). The reverse is also true, as LBs
are observed frequently in AD. A review of autopsied
cases from the Washington University Alzheimer
Disease Research Center (ADRC) suggests that as
many as 25% of autopsied AD cases have cortical/
limbic LBs in sufficient quantity to be classified as
mixed DLB/AD, although most did not clinically
manifest the distinctive symptoms of DLB.2,3 Other
autopsy series confirm the high co-occurrence of DLB
and AD.4,5
Although there are published criteria for the clin-
ical features of DLB,3 these criteria appear to best
capture the “pure” DLB cases. It is unclear how well
the criteria capture the more common mixed
DLB/AD group, many of whom may be misclassified
clinically as probable AD.1 Diagnostic criteria for
DLB include progressive cognitive decline plus at
least two of the following: parkinsonism, visual hal-
lucinations, or cognitive fluctuation.3 Because neuro-
psychological studies of well-characterized samples
with confirmed neuropathology are lacking, the spe-
cific cognitive features of DLB and its rate of pro-
gression remains unclear.6-9 Some studies suggest
that DLB is marked by specific declines in executive
function10,11 and visuospatial ability,12-17 but others
find a visuospatial deficit alone.18-20 Interpretation of
these findings is limited by failure to test across
multiple cognitive domains, small sample sizes, and
contamination of the DLB patient groups with vary-
ing levels of AD pathology.
This report describes cross-sectional and longitu-
dinal performance on a battery of cognitive tests in
people with autopsy-confirmed pure DLB, pure AD,
and mixed DLB/AD. Our goals were to determine
which tests differed among the groups, whether rates
of cognitive decline varied, and whether differences
could be attributed to either verbal, visuospatial, or
executive domains. Analyses with autopsy-confirmed
diagnoses, irrespective of antemortem clinical diag-
nosis, are an important first step in defining the
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cognitive deficits associated with the synucleinopathies
and hence to improve clinical diagnostic criteria.
Methods. Case selection. Cases were selected from volunteers
who enrolled in a longitudinal study of healthy aging and demen-
tia. Initiated in 1979, a total of 2,716 individuals have been en-
rolled and 842 have come to autopsy.21,22 Demographic data and
diagnoses at expiration are reported in tables 1 and 2. The pure
and mixed DLB samples included all available cases. Pure AD
cases were selected to be similar in age, education, and dementia
severity to the combined pure DLB and DLB/AD groups and
drawn at random from a total of 483 available AD-confirmed au-
topsies. The combined data reported here span 23 years and thus
include only the available clinical and psychometric scores com-
mon to all participants. Although previous research from our cen-
ter has indicated that depression, a common comorbidity of
dementia, does not worsen performance on the battery of psycho-
metric tests used here23 and that other comorbidities do not influ-
ence the rate of progression of dementia of the Alzheimer type,24
autopsied cases with other comorbid disorders that could poten-
tially cause dementia (e.g., cerebrovascular disease) were excluded
from this sample. The Washington University Human Studies
Committee approved all procedures
Clinical assessment. Experienced clinicians conducted inde-
pendent semistructured interviews with the participant and a
knowledgeable collateral source at the initial visit and annually
thereafter. The Clinical Dementia Rating (CDR),21,22,25 was used to
determine the presence or absence of dementia and, if present,
stage its severity.26 The CDR rates cognitive function in each of six
categories (memory, orientation, judgment, problem solving, per-
formance in community affairs, and home and hobbies and per-
sonal care). Scores are derived from information gathered at the
clinical assessment but without reference to psychometric perfor-
mance. Two scores result. The global CDR synthesizes the six
categories. CDR 0 indicates no dementia and CDR 0.5, 1, 2, or 3
correspond to very mild, mild, moderate, or severe dementia. The
second score is “sum of boxes” that refers to the sum of the scores
in all six categories and provides a quantitative expansion of the
CDR ranging from 0 (no impairment) to 18 (maximum impair-
ment).27 The diagnostic criteria for AD used for this study are
consistent with “probable AD” according to the National Institute
of Neurologic and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association.28 Pub-
lished criteria were used for DLB.3 The CDR has been validated in
studies of all forms of dementia, is sensitive to clinical progres-
sion, and correlates highly with autopsy-confirmed AD.22,26,29 The
criteria used to diagnose DLB have been evolving since the incep-
tion of the McKeith criteria, and many of the participants with
pure DLB and DLB/AD enrolled in the current study before their
implementation. As a result, diagnostic criteria for AD has been
historically more accurate and prevalent, as shown in table 2.
Table 1 also presents an aggregated report of psychiatric symp-
toms experienced by the participant at any time during the re-
Table 1 Sample demographics
Pure AD, n  66 DLB/AD, n  57 Pure DLB, n  9 F(2,129)
Age 77.0 (8.1) 75.2 (9.7) 72.6 (5.7) 1.34
Age at death 83.5 (7.5)a 80.0 (8.9)b 77.2 (5.8)b 4.41*
Years before death 6.6 (3.7)a 4.7 (3.5)b 4.6 (2.4)b 4.44*
Years of education 13.3 (3.7) 12.9 (3.9) 12.9 (2.4) 0.14
Gender (M/F) 39/27 31/26 8/1 4.44†
Visual hallucinations 4 11 4 6.94*†
Hearing voices 1 7 3 8.75*†
Smelling odors 1 0 1 3.82†
Feelings of being spied on 10 15 3 1.13†
Controlled by others 1 0 1 3.82†
Sent special messages 1 1 0 0.38†
CDR 0.5 21 17 4
CDR 1.0 29 25 4
CDR 2.0 13 12 1
CDR 3.0 3 3 0
Sum of boxes 6.4 (4.3) 6.6 (3.9) 4.6 (2.7) 1.06
Blessed Dementia Scale‡ 14.5 (7.8)a 15.1 (8.9)a 6.1 (4.9)b 4.19*
Means within the same row sharing the same superscript (a or b) are equivalent. Bonferroni correction was applied to all paired
comparisons.
* p  0.05.
† Likelihood ratio (2, n  132).
‡ Number of participants vary due to incomplete data (pure Alzheimer disease [AD]  48, dementia with Lewy bodies [DMB]/AD  52,
and pure DLB  8; F[2,105]).
Table 2 Clinical diagnoses at expiration
Pure AD DLB/AD Pure DLB
Dementia of the Alzheimer
type (pure)
60 36 3
Dementia of the Alzheimer
type with secondary
parkinsonism or DLB
4 10 2
Pure DLB 0 5 2
Uncertain dementia 1 2 1
Other forms of dementia
(e.g., vascular, frontotemporal)
1 4 1
AD  Alzheimer disease; DLB  dementia with Lewy bodies.
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ported longitudinal course of study (answered in a yes/no format
by an informant).30
Psychometric assessment. A 90-minute psychometric battery
was administered annually to all participants approximately 2
weeks after of the clinical assessment to assess multiple cognitive
domains: primary memory (Wechsler Memory Scale [WMS] Digits
Forward),31 working memory (WMS Digits Backward),31 episodic
memory (WMS Logical Memory and Associate Learning,31 Benton
Visual Retention Test: Form C-Recall),32 semantic memory (Word
Fluency,33 Boston Naming Test),34 and visuospatial/constructive
(Wechsler Adult Intelligence Scale [WAIS] Digit Symbol and Block
Design,35 Benton Visual Retention Test: Form D-Copy,32 Trailmak-
ing A),36 and a simple test of motor speed (Crossing Off).37 Al-
though these data originally were collected to investigate the
clinical features of AD, the assessment protocol is sufficiently
broad to test aspects of concentration and visuospatial domains as
well as different aspects of memory. Psychometric data from the
final time of assessment with fewer than three missing data
points was used for the cross-sectional analyses; this final assess-
ment averaged 5.7 years before death. Longitudinal analyses in-
cluded all times of psychometric assessment and ranged from two
to 20 assessments.
Neuropathologic assessment. All brains were examined with a
standard protocol.22,38 Following fixation in neutral buffered 10%
formalin, tissue blocks were taken from 30 brain regions. Sections
(6 m) from paraffin-embedded tissue blocks were stained with
hematoxylin-eosin, Gallyas, and modified Bielchowsky silver
stains and immunohistochemical methods.22,38 Two separate crite-
ria for AD were used. One was based on quantification of diffuse
and neuritic amyloid deposition in ten cortical regions.22,38 In addi-
tion, National Institute on Aging-Reagan neuropathologic proba-
bility estimates of AD were calculated for each case.39 The two sets
of criteria have nearly complete diagnostic agreement. DLB patho-
logic diagnoses were made according to published criteria3 using
-synuclein to screen for LBs. In this study, only cases with both
neocortical and limbic LBs were included in the analyses. Termi-
nal cases of AD (CDR 3) with LBs present limited to amygdala
were not included.40
Statistical analyses. Factor analysis (Varimax rotation) was
completed on psychometric raw scores. Factor extraction was
based on both the Kaiser-Guttman rule of retaining components
with eigenvalues 1 and inspection of screen plots of eigenvalues
vs their ordinal positions. Although the sample size does not sat-
isfy more conservative rules of factor analysis,41,42 this sample size
satisfies the subject-to-variable ratio rule of thumb (10:1) as cited
by Nunnally and Bernstein43, which has been supported by recent
Monte Carlo studies findings, indicating that these ratios are suf-
ficiently powerful to establish preliminary clinical results when
the total sample size is 100.44 Between-group comparisons of
quantitative measures were conducted using analysis of variance
(ANOVA) followed by Bonferroni corrected post hoc comparisons.
The 2 test of independence was used for nominal variables. Lon-
gitudinal rates of cognitive decline on the psychometric measures
were compared for the three groups using a random effects mixed
model (PROC Mixed in SAS). This method was chosen because it
is least susceptible to premorbid cognitive ability biases (intercept
effects) by comparing average slopes of cognitive decline between
groups.
Results. Cross-sectional analyses. Factor analysis on
raw scores from the current sample confirmed a two-factor
solution that replicates established indices of verbal mem-
ory and visuospatial ability found previously by our group
using psychometric data from volunteers with pure AD.45
Group means and SDs of the psychometric tests and factor
scores are reported in table 3 (rotated eigenvalues  4.99
and 4.14, 70% of variance explained;tables 3 and 4).
ANOVAs indicated group differences on both factors
(F(2,129)  23.00, p  0.001; F(2,129)  6.82, p  0.01).
Bonferroni corrected paired comparisons indicated that the
pure DLB and DLB/AD did not differ on the visuospatial
factor but that both groups scored significantly worse on
Table 3 Means and SDs
Pure AD DLB/AD Pure DLB F(2,129)
Visuospatial factor 0.51  0.92a 0.52  0.83b 0.42  0.70b 22.69*
Trailmaking A (s†) 87.41  50.07a 145.81  47.54b 121.89  50.49ab 21.81*
WAIS Block Design 16.65  10.76a 7.44  8.97b 10.56  10.78ab 13.06*
WAIS Digit Symbol 22.12  14.37a 9.07  11.14b 18.11  8.67ab 16.14*
Benton Recall Correct 2.68  2.00a 1.39  1.52b 2.33  1.50ab 8.21*
Benton Copy Correct 7.64  3.29a 5.51  3.82b 6.67  3.04ab 5.60‡
Crossing Off 124.08  50.49a 90.65  57.90b 116.89  46.64ab 6.04‡
Verbal factor 0.16  0.86a 0.01  1.10a 1.09  0.67b 6.73‡
WMS Logical Memory (immediate recall) 2.20  2.02a 2.02  2.59a 5.28  3.35b 7.53*
Boston Naming Test 34.92  17.08a 31.86  17.59a 51.67  5.34b 5.40‡
WAIS Information 11.41  6.62a 10.54  6.75a 17.00  5.68b 3.70§
Word Fluency 18.03  10.65a 12.68  10.90b 16.22  8.24ab 3.90§
WMS Associate Learning 5.88  3.27 5.61  3.69 7.78  4.76 1.44
WMS Digits Forward 5.68  1.76 4.98  1.92 6.33  1.32 3.50
WMS Digits Backward 3.45  1.70 2.74  1.63 3.22  0.83 2.98
Means within the same row sharing the same superscript (a or b) are equivalent. Bonferroni correction was applied to all paired
comparisons.
* p  0.001.
† High scores indicate worse performance.
‡ p  0.01.
§ p  0.05.
AD  Alzheimer disease; DLB  dementia with Lewy bodies; WMS  Wechsler Memory Scale; WAIS  Wechsler Adult Intelligence
Scale.
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this factor than the pure AD group. The pure AD and
DLB/AD groups did not differ on the verbal factor, but both
groups scored significantly worse than the pure DLB
group. Further, multivariate F tests indicated that the
patterns of scores on the component subtests that made up
each factor differed (F(12,250)  3.53, p  0.001; F(14,248) 
2.85, p  0.001).
To determine which measures contributed to the ob-
served group differences, univariate ANOVAs of the indi-
vidual psychometric tests were also conducted (table 3).
There were significant group differences on all visuospatial
tests. The pattern of means was similar on all measures.
The pure AD group performed best, followed by the pure
DLB group, and then the mixed DLB/AD. Because many of
these tests are speeded, group differences on the visuospa-
tial tasks were reexamined using Crossing Off to control
for motor slowing due to Parkinsonism and sum of boxes to
control for dementia severity. The results remained un-
changed. Although better motor scales exist in the litera-
ture to assess motor slowing (e.g., Unified PD Rating
Scale),46 Crossing Off was the only measure available for
the entire sample.
There were also significant group differences on four of
the seven measures of verbal memory: WMS Logical Mem-
ory, Boston Naming Test, WAIS Information, and Word
Fluency. The pure DLB group performed best on all but
one measure (Word Fluency) followed by the pure AD
group and then the mixed DLB/AD group. Although the
level of dementia was slightly lower for the pure DLB
group, results remained unchanged if the CDR sum of
boxes was used as a statistical control for dementia sever-
ity. Because of the small pure DLB group size in all post
hoc, comparisons were repeated using the Mann–Whitney
U nonparametric test. Results remained essentially un-
changed (pure AD and pure DLB group differences become
significant on one additional measure in each the visuo-
spatial and verbal domains: Trailmaking and Associate
Learning). In terms of behavioral manifestations, partici-
pants with pure DLB and DLB/AD experienced signifi-
cantly more visual and auditory hallucinations than did
the pure AD participants (table 1).
Longitudinal analyses. As expected, analyses of the
longitudinal factors scores and individual psychometric
tests indicated the presence of a main effect of time; pro-
gressive cognitive impairment was noted across both
visuospatial and memory domains in all three groups (all F
values 24.92, all p values 0.001). In contrast, none of
the group 	 time interactions were significant (all F val-
ues 1.63, all p values 0.23). Thus, the rate of longitudi-
nal cognitive decline for the pure DLB, DLB/AD, and AD
groups were equivalent.
Discussion. Using data from a well–characterized
longitudinal sample with neuropathologic confirma-
tion, the current findings indicate that unlike other
comorbidities of AD,23,24 the presence of LB neuropa-
thology significantly changes the cognitive presenta-
tion of AD but does not affect rates of cognitive
decline once dementia is present.
First, results indicate that the presence of LB pa-
thology alone is not associated with the verbal mem-
ory deficits witnessed in AD. These findings are
consistent with other preliminary reports in the lit-
erature.47 Pure DLB participants performed signifi-
cantly better on all tests of verbal memory than did
pure AD or mixed DLB/AD participants. Further, the
DLB/AD performance was roughly equivalent to the
AD participants on the verbal composite score and
its subtests, indicating that LB and AD neuropatho-
logic burden did not produce worse verbal memory in
the combined group. The relative preservation of ver-
bal skills in DLB may be an important feature of
DLB that can aid in its clinical diagnosis in life.
Second, the pure AD and pure DLB groups were
statistically equivalent on all tests of visuospatial
ability, although individual subtest scores of the
pure DLB group were generally lower than the
scores of the pure AD group. This finding was sur-
prising because current diagnostic criteria and find-
ings of others12-17 predict that those with pure DLB
should perform much worse than those with pure AD
in visuospatial ability. Only when a composite score
of the individual tests was computed based on factor
analysis did the groups differ significantly. Given the
relatively low number of subjects in the pure DLB
group, the purer measure of visual spatial ability
was needed to attenuate error and increase sensitiv-
ity to detect the visuospatial decrement. Although a
larger sample of pure DLB participants may increase
the sensitivity of statistical tests for individual
subtests, the composite scoring method is a more
sensitive index than any single test. Given the rarity
of pure DLB and the intensiveness of longitudinal
study, the composite score is an efficient index of
visuospatial deficits in DLB.
In contrast to the pure DLB participants, the com-
Table 4 Rotated component matrix
Psychometric test
Factor 1
visuospatial
Factor 2
verbal
Visuospatial factor
WAIS Digit Symbol 0.88 0.26
Trailmaking A (s) 0.87 0.24
WAIS Block Design 0.87 0.21
Benton Recall Correct 0.78 0.32
Benton Copy Correct 0.77 0.34
Crossing Off 0.68 0.29
Verbal Factor
WAIS Information 0.25 0.85
WMS Logical Memory 0.17 0.82
WMS Associate Memory 0.22 0.82
Boston Naming Test 0.33 0.75
WMS Digits Forward 0.38 0.64
WMS Digits Backward 0.54 0.58
Word Fluency 0.59 0.56
% Explained variance 38 32
WAIS  Wechsler Adult Intelligence Scale; WMS  Wechsler
Memory Scale.
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bined DLB/AD participants performed significantly
worse on the visuospatial composite score and all its
component subtests. Thus, the presence of both dis-
eases produced poorer visuospatial performance than
either pathologic burden alone. Unlike the verbal
memory factor, the co-occurrence of the two diseases
appears to interact, as evidenced by the significantly
lower visuospatial scores, both composite and indi-
vidual test scores.
Finally, the three groups were equivalent in the
longitudinal analyses, indicating that the rate of de-
cline was comparable across all three groups in both
the visuospatial and verbal memory domains. Some-
what surprisingly, the presence of both LB and AD
neuropathologies did not change the rate of demen-
tia progression over the 4.5-year course measured.
This suggests that LBs in the presence of AD
plaques and tangles adds a selective visuospatial
cognitive deficit but does not accelerate the dement-
ing process in either the visuospatial or verbal mem-
ory domains. Further, the significant main effects in
the longitudinal analyses indicate that the observed
differences at the selected cross-sectional moment
were present at enrollment (presumably before the
clinical detection of the dementia) and persisted
throughout the course of the disease. These longitu-
dinal results extend the findings reported by others
investigators.48,49
As a retrospective study, these findings have sev-
eral limitations. First, volunteers who complete
brain donation may not represent the population at
large. Diagnosis of DLB in life is difficult (table 2),
and the neuropathologic confirmed cases presented
here may represent a sampling bias. Until diagnostic
criteria for DLB are refined and the clinicopathologic
features of the disease are known, this potential lim-
itation will continue to be an issue in clinical DLB
research.
Second, a valid criticism of the cross-sectional de-
sign of this study is that the observed lack of differ-
ences between the pure DLB and AD groups on the
individual visuospatial subtests may have been due
to the fact that the pure DLB participants were not
matched well to the other groups. The pure DLB
group contains more men, became demented at a
younger age, and died earlier, which may have re-
sulted in their relatively lower dementia ratings (see
CDR and Blessed Dementia Scale30 scores in table 1).
The pure DLB group represents a convenience sam-
ple of those individuals presenting for evaluation;
however, every attempt was made to match the over-
all sample at the cross-sectional moment on gender
and dementia rating. The gender distribution of our
sample is consistent with other reports of male pre-
dominance in DLB.50 Further, the longitudinal anal-
yses used a random effects mixed linear model
because it is less susceptible to premorbid cognitive
ability biases (intercept effects) by comparing aver-
age slopes of cognitive decline between groups. Thus,
every individual serves as his or her own control
reducing any biases that may occur with poor match-
ing of the samples. Finally, all analyses were run
with the dementia level statistically controlled. This
did not substantially change any of the current find-
ings. Ultimately, this clinical sample used all avail-
able participants who had come to postmortem
examination, and one must judge the reliability of
the test results by weighing the homogeneity of the
sample (i.e., the pure DLB group were uniquely bur-
dened by LB pathology) vs the statistical sensitivity
of the tests and the effect sizes noted in table 3.
Third, variables selected for these analyses may
not optimally capture the all clinical differences be-
tween the DLB and AD. For example, the pattern of
visuospatial and verbal test scores across the psycho-
metric battery suggests that there may be an impor-
tant attention/executive function component to the
cognitive deficits associated in mixed DLB/AD. Al-
though an executive functioning factor was not indi-
cated by this factor analysis, three visuospatial tasks
with significant attention demands were signifi-
cantly impaired in the mixed dementia group (Trail-
making A, Block Design, and Digit Symbol). Further,
the verbal tasks that did not load very highly on the
verbal factor have significant executive components
as part of successful test performance. Several re-
ports in the literature site attentional deficits,12-17
but the tasks used are often speeded, thus confound-
ing true cognitive impairment with motor slowing
due to parkinsonism. Notably, all visuospatial differ-
ences remained significant even after motor slowing
was statistically controlled.
Unfortunately, to test the attentional hypothesis
robustly, a battery of more difficult visual attention
tests is needed. For example, Trailmaking B may be
a better test of executive function in the visuospatial
domain, but it has not been consistently included in
the ADRC longitudinal battery and thus data were
not available for most of the participants in this re-
port. Other tasks testing specific attentional modali-
ties (e.g., Stroop task)51 are not part of the standard
ADRC battery and therefore may have precluded us
from replicating the attention deficits previously de-
scribed.13 With a wider sampling of tests of visual
attention and executive functioning domains, other
cognitive changes associated with DLB might be de-
tected and an executive factor may be indicated.
Other tasks that have been used to discriminate
DLB from AD include both unspeeded tasks (Wiscon-
sin Card Sort,52 Ravens Progressive Matrices,53 Embed-
ded Figures Test,54 and Clock Drawing)34 and speeded
tasks (Trailmaking A and B, Stroop task, and select
WAIS subtests55,56 Block Design, Digit Symbol, Picture
Arrangement, and Object Assembly).
Overall, these cross-sectional and longitudinal
analyses are encouraging because they indicate that
LB pathology in the presence of AD results in disso-
ciable deficits that may be used to identify partici-
pants with either or both dementia pathologies. The
visuospatial/verbal memory differences observed
here were consistent across groups, persisted across
time, and occurred very early in the dementing pro-
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cess. Further, these data suggest that the presence
of LBs alone may not produce the verbal memory
deficits seen in AD or the frank visuospatial deficits
suspected by current clinical criteria. When both dis-
eases are present, the effect of LB and AD patholo-
gies appear to be additive, wherein visuospatial
performance suffers more in the presence of com-
bined pathologies than with AD or LB pathologies
alone. In contrast, there was no evidence that the
combined pathologies accelerate the course of de-
cline. Importantly, the combined longitudinal and
cross-sectional results present an integrated snap-
shot of a broad set of findings from other cross-
sectional clinical research.20,57-59 Domain-specific
testing may be one way to distinguish clinically the
two types of dementia in life. Future investigations
of cognitive impairment due to neuropathologic con-
firmed LB and AD pathology may help to refine the
diagnostic criteria to discriminate better patients
with pure DLB vs the more common mixed AD/DLB
presentation. The application of quantitative pathol-
ogy burden counts instead of categorical diagnostic
groups may also add to future investigations of the
impact that LBs have on cognitive function.
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